Subtopic Deep Dive
IDH Mutations in Gliomas
Research Guide
What is IDH Mutations in Gliomas?
IDH mutations refer to somatic alterations in IDH1 and IDH2 genes that produce neomorphic enzymes converting α-ketoglutarate to the oncometabolite 2-hydroxyglutarate in gliomas.
IDH1/2 mutations occur in over 70% of lower-grade gliomas and secondary glioblastomas (Yan et al., 2009, 5790 citations). These mutations define molecular classes more predictive than histology, integrating with 1p/19q codeletion and TP53 status (Brat et al., 2015, 3149 citations). Mutant IDH induces a CpG island hypermethylator phenotype sufficient for gliomagenesis (Turcan et al., 2012, 1934 citations).
Why It Matters
IDH mutations stratify glioma prognosis and guide therapy; 1p/19q-codeleted IDH-mutant oligodendrogliomas respond best to PCV chemotherapy plus radiotherapy (Cairncross et al., 2012, 1142 citations). They enable risk-adapted management in EANO guidelines, distinguishing IDH-wildtype glioblastoma from IDH-mutant lower-grade tumors (Weller et al., 2020, 1728 citations). Population studies show IDH status prevalence varies by age and histology, informing trials (Ostrom et al., 2014, 2220 citations; Ostrom et al., 2020, 1880 citations).
Key Research Challenges
Therapeutic Targeting Vulnerabilities
IDH inhibitors like ivosidenib show promise but face resistance in gliomas unlike leukemias. Mutant gliomas exhibit metabolic rewiring beyond 2-HG production (Yan et al., 2009). Clinical translation lags due to blood-brain barrier issues (Tan et al., 2020).
Molecular Subclass Concordance
Histology poorly predicts IDH/1p19q/ATRX status, requiring integrated genomics (Brat et al., 2015). Hypermethylation phenotype from IDH alone insufficiently explains progression (Turcan et al., 2012). Standardized diagnostics needed per EANO guidelines (Weller et al., 2020).
Epidemiologic Heterogeneity
IDH prevalence drops with grade; young adults show higher rates than elderly (Ostrom et al., 2014). CBTRUS data reveal underreporting of molecular subtypes (Ostrom et al., 2020). Longitudinal studies needed for incidence trends.
Essential Papers
<i>IDH1</i>and<i>IDH2</i>Mutations in Gliomas
Hai Yan, D. Williams Parsons, Genglin Jin et al. · 2009 · New England Journal of Medicine · 5.8K citations
Mutations of NADP(+)-dependent isocitrate dehydrogenases encoded by IDH1 and IDH2 occur in a majority of several types of malignant gliomas.
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
Daniel J. Brat, Roel G.W. Verhaak, Kenneth D. Aldape et al. · 2015 · New England Journal of Medicine · 3.1K citations
The integration of genomewide data from multiple platforms delineated three molecular classes of lower-grade gliomas that were more concordant with IDH, 1p/19q, and TP53 status than with histologic...
The epidemiology of glioma in adults: a "state of the science" review
Quinn T. Ostrom, Luc Bauchet, Faith G. Davis et al. · 2014 · Neuro-Oncology · 2.2K citations
Gliomas are the most common primary intracranial tumor, representing 81% of malignant brain tumors. Although relatively rare, they cause significant mortality and morbidity. Glioblastoma, the most ...
Management of glioblastoma: State of the art and future directions
Aaron C. Tan, David M. Ashley, Giselle Y. López et al. · 2020 · CA A Cancer Journal for Clinicians · 2.0K citations
Abstract Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for patients with this disease is poor, with a median survival of <2 years. There is a slight predo...
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Şevin Turcan, Daniel Rohle, Anuj Goenka et al. · 2012 · Nature · 1.9K citations
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017
Quinn T. Ostrom, Nirav Patil, Gino Cioffi et al. · 2020 · Neuro-Oncology · 1.9K citations
Abstract The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control (CDC) and National Cancer Institute (NCI), is the largest population-b...
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Michael Weller, Martin J. van den Bent, Matthias Preusser et al. · 2020 · Nature Reviews Clinical Oncology · 1.7K citations
Abstract In response to major changes in diagnostic algorithms and the publication of mature results from various large clinical trials, the European Association of Neuro-Oncology (EANO) recognized...
Reading Guide
Foundational Papers
Start with Yan et al. (2009) for mutation discovery in gliomas, then Turcan et al. (2012) for hypermethylator phenotype, followed by Watanabe et al. (2009) for early event timing and Cairncross et al. (2012) for 1p19q therapy.
Recent Advances
Brat et al. (2015) for TCGA classes; Weller et al. (2020) for EANO diagnostics; Tan et al. (2020) for GBM management; Ostrom et al. (2020) for epidemiology.
Core Methods
Sanger sequencing or NGS for IDH1/2; IHC for R132H; methylation arrays for glioma subtype; FISH for 1p19q; integrated classifiers per WHO 2021.
How PapersFlow Helps You Research IDH Mutations in Gliomas
Discover & Search
Research Agent uses searchPapers('IDH1 mutations gliomas prognosis') to retrieve Yan et al. (2009) as top hit with 5790 citations, then citationGraph to map forward citations to Brat et al. (2015) and backward to Watanabe et al. (2009), while exaSearch uncovers epidemiological links in Ostrom et al. (2014).
Analyze & Verify
Analysis Agent applies readPaperContent on Turcan et al. (2012) to extract hypermethylator mechanisms, verifies claims via verifyResponse (CoVe) against Brat et al. (2015), and runs PythonAnalysis with pandas to meta-analyze survival data from RTOG 9402 (Cairncross et al., 2012), graded A via GRADE for randomized evidence.
Synthesize & Write
Synthesis Agent detects gaps in IDH inhibitor trials post-Tan et al. (2020), flags contradictions between histology and molecular classes in Weller et al. (2020), then Writing Agent uses latexEditText for review drafting, latexSyncCitations for 10+ papers, and latexCompile for camera-ready output with exportMermaid for IDH-1p19q pathway diagrams.
Use Cases
"Meta-analyze survival HR from IDH-mutant vs wildtype gliomas across 5 trials"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis of HR/CI from Yan 2009, Brat 2015, Cairncross 2012) → GRADE A-verified forest plot CSV.
"Draft LaTeX review section on IDH hypermethylation with citations and figure"
Synthesis Agent → gap detection in Turcan 2012 → Writing Agent → latexEditText + latexSyncCitations (Yan 2009 et al.) + latexGenerateFigure (hypermethylator model) → latexCompile PDF.
"Find code for IDH mutation simulator from glioma papers"
Research Agent → paperExtractUrls (Brat 2015 supplements) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runnable Python model of 2-HG production.
Automated Workflows
Deep Research workflow scans 50+ IDH-glioma papers via searchPapers → citationGraph, producing structured report with prevalence tables from Ostrom datasets. DeepScan applies 7-step CoVe to verify Yan et al. (2009) mutation frequency claims against CBTRUS (Ostrom 2020). Theorizer generates hypotheses on IDH-TP53 co-mutations from Brat et al. (2015) integrations.
Frequently Asked Questions
What defines IDH-mutant gliomas?
IDH1 R132H or IDH2 R172 mutations producing 2-HG oncometabolite, occurring in 70-80% lower-grade gliomas and secondary GBMs (Yan et al., 2009).
What methods detect IDH mutations?
Immunohistochemistry for R132H (95% sensitive), sequencing for non-canonical mutations, integrated with 1p19q FISH per WHO and EANO guidelines (Weller et al., 2020; Brat et al., 2015).
What are key papers on IDH in gliomas?
Yan et al. (2009, 5790 citations) discovered mutations; Turcan et al. (2012, 1934 citations) linked to hypermethylation; Cairncross et al. (2012, 1142 citations) showed 1p19q-IDH therapy benefits.
What open problems exist?
IDH inhibitor resistance mechanisms, blood-brain delivery, co-mutation interactions with ATRX/TP53, and elderly patient stratification (Tan et al., 2020; Weller et al., 2020).
Research Glioma Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching IDH Mutations in Gliomas with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Glioma Diagnosis and Treatment Research Guide